[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571327":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":36,"collaborators":10,"id":38,"slug":10,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Beijing Anlong Biopharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"The subjects received AL-001 ophthalmic injection",null,"Evaluate long-term safety and efficacy",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"AnlongBio","CONTACT","+86-010-80414166","info@anlongbio.com",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":10,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Chinese Academy of Medical Sciences & Peking Union Hospital","RECRUITING","Beijing","Beijing Municipality","China",{"type":26,"coordinates":27},"Point",[28,29],116.39723,39.9075,{"lat":29,"lon":28},[32],{"name":33,"role":15,"phone":34,"phoneExt":10,"email":35},"YouxinChen","+86-010-65296358","chenyouxinpumch@163.com",{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571327",false,"NCT06718816","Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD","A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)","Inclusion Criteria:\n\n* The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.\n* The subject or their legal representative agrees to participate in this study and signs a written ICF.\n* The subjects are willing and able to follow planned visits and procedures.\n\nExclusion Criteria:\n\n* None","ALL","50 Years",{"count":47,"type":48},21,"ESTIMATED","OBSERVATIONAL","This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.",[52],"Wet Age-related Macular Degeneration (wAMD)","2024-12-02",{"date":55,"type":56},"2024-12-05","ACTUAL",{"date":58,"type":48},"2024-12-09",{"date":60,"type":48},"2029-06-30",{"name":5,"class":6},1]